Review

You have full text access to this OnlineOpen article

T cell epitope–specific immune therapy for rheumatic diseases

  1. Salvatore Albani1,*,
  2. Berent Prakken2

Article first published online: 29 DEC 2005

DOI: 10.1002/art.21520

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 1, pages 19–25, January 2006

Additional Information

How to Cite

Albani, S. and Prakken, B. (2006), T cell epitope–specific immune therapy for rheumatic diseases. Arthritis & Rheumatism, 54: 19–25. doi: 10.1002/art.21520

Author Information

  1. 1

    University of California San Diego, and Androclus Therapeutics, San Diego, California

  2. 2

    University Medical Center Utrecht, and Wilhelmina Children's Hospital, Utrecht, The Netherlands

*Departments of Medicine and Pediatrics, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0663

Publication History

  1. Issue published online: 29 DEC 2005
  2. Article first published online: 29 DEC 2005
  3. Manuscript Accepted: 21 SEP 2005
  4. Manuscript Received: 29 MAR 2005

Funded by

  • NIH. Grant Numbers: 5P50-AR-44850-04, N01-AR-9-2241, 2R01-AI-41721-05, 1R01-AR-48084-01
  • Dutch Organization for Scientific Research NWO VIDI
  • Fifth European Framework

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (66K)

REFERENCES

  • 1
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16.
  • 2
    Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619–32.
    Direct Link:
  • 3
    Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 212–7.
  • 4
    Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T cell–independent mechanisms from beginning to end [review]. Arthritis Rheum 2002; 46: 298–308.
    Direct Link:
  • 5
    Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426: 454–60.
  • 6
    Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998; 10: 669–76.
  • 7
    Gracie JA, Leung BP, McInnes IB. Novel pathways that regulate tumor necrosis factor-α production in rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 270–5.
  • 8
    Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004; 114: 471–4.
  • 9
    Huizinga TW, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46: 1155–9.
    Direct Link:
  • 10
    Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167–79.
  • 11
    Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. Curr Opin Rheumatol 2001; 13: 177–83.
  • 12
    Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFα therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22: 252–8.
  • 13
    Taylor PC, Williams RO, Maini RN. Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001; 13: 611–6.
  • 14
    Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 323–8.
  • 15
    Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 2002; 29: 220–9.
  • 16
    Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4 [review]. Nat Rev Immunol 2001; 1: 220–8.
  • 17
    Kremer JM, Westhovens R, Leon M, di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907–15.
  • 18
    Steinman L. Immune therapy for autoimmune diseases. Science 2004; 305: 212–6.
  • 19
    Teklenburg G, Albani S. The role of immune tolerance in preventing and treating arthritis. Curr Rheumatol Rep 2004; 6: 434–41.
  • 20
    Joosten LA, Coenen-de Roo CJ, Helsen MM, Lubberts E, Boots AM, van den Berg WB, et al. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen–induced arthritis. Arthritis Rheum 2000; 43: 645–55.
    Direct Link:
  • 21
    Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N, et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 2001; 44: 1993–7.
    Direct Link:
  • 22
    Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39: 623–8.
    Direct Link:
  • 23
    Sieper J, Kary S, Sorensen H, Alten R, Eggens U, Huge W, et al. Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996; 39: 41–51.
    Direct Link:
  • 24
    Kalden JR, Sieper J. Oral collagen in the treatment of rheumatoid arthritis [editorial]. Arthritis Rheum 1998; 41: 191–4.
    Direct Link:
  • 25
    Cobb BA, Kasper DL. Coming of age: carbohydrates and immunity. Eur J Immunol 2005; 35: 352–6.
    Direct Link:
  • 26
    Yamada H, Dzhambazov B, Bockermann R, Blom T, Holmdahl R. A transient post-translationally modified form of cartilage type II collagen is ignored by self-reactive T cells. J Immunol 2004; 173: 4729–35.
  • 27
    Dzhambazov B, Holmdahl M, Yamada H, Lu S, Vestberg M, Holm B, et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 2005; 35: 357–66.
    Direct Link:
  • 28
    Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004; 114: 582–8.
  • 29
    Cope AP, Sonderstrup G. Evaluating candidate autoantigens in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20: 23–39.
  • 30
    Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001; 166: 1492–8.
  • 31
    Prakken B, Kuis W, van Eden W, Albani S. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 2002; 4: 466–73.
  • 32
    Quintana FJ, Carmi P, Mor F, Cohen IR. Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: immune cross-regulation with the 60-kd heat-shock protein. Arthritis Rheum 2004; 50: 3712–20.
    Direct Link:
  • 33
    Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. J Clin Invest 2004; 114: 1227–32.
  • 34
    Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003; 362: 469–76.
  • 35
    Van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation [review]. Nat Rev Immunol 2005; 5: 318–30.
  • 36
    Albani S, Keystone EC, Nelson JL, Ollier WE, la Cava A, Montemayor AC, et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1995; 1: 448–52.
  • 37
    Albani S, Ravelli A, Massa M, de Benedetti F, Andree G, Roudier J, et al. Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J Pediatr 1994; 124: 561–5.
  • 38
    Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol Today 1996; 17: 466–70.
  • 39
    Prakken AB, van Eden W, Rijkers GT, Kuis W, Toebes EA, de Graeff-Meeder ER, et al. Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39: 1826–32.
    Direct Link:
  • 40
    De Graeff-Meeder ER, van Eden W, Rijkers GT, Prakken AB, Kuis W, Voorhorst-Ogink MM, et al. Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favourable course of arthritis. J Clin Invest 1995; 95: 934–40.
  • 41
    Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991; 12: 105–10.
  • 42
    Cope AP, Patel SD, Hall F, Congia M, Hubers HA, Verheijden GF, et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis–associated and nonassociated HLA–DR4 alleles. Arthritis Rheum 1999; 42: 1497–507.
    Direct Link:
  • 43
    Rook GA, Ristori G, Salvetti M, Giovannoni G, Thompson EJ, Stanford JL. Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders. Immunol Today 2000; 21: 503–8.
  • 44
    Steinman L. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. J Exp Med 2001; 194: F27–30.
  • 45
    Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A 2004; 101: 4228–33.
  • 46
    La Cava A, Nelson JL, Ollier WE, MacGregor A, Keystone EC, Thorne JC, et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J Clin Invest 1997; 100: 658–63.
  • 47
    Holz A, Bielekova B, Martin R, Oldstone MB. Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol 2000; 164: 1103–9.
  • 48
    Bielekova B, Muraro PA, Golestaneh L, Pascal J, McFarland HF, Martin R. Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7. J Neuroimmunol 1999; 100: 115–23.
  • 49
    Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000; 6: 1176–82.
  • 50
    Massa M, Campanelli R, Uccelli A, Meli V, Lanza P, Billetta R, et al. Identification of novel lead compounds in modulation of pathogenic immune responses in multiple sclerosis. Budapest: International Conference on Autoimmunity; 2004.
  • 51
    Kamphuis S, Kuis W, de Jager W, Teklenburg G, Massa M, Gordon G, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005; 366: 50–6.
  • 52
    De Kleer IM, Kamphuis SM, Rijkers GT, Scholtens L, Gordon G, de Jager W, et al. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum 2003; 48: 2001–10.
    Direct Link:
  • 53
    Prakken BJ, Carson DA, Albani S. T cell repertoire formation and molecular mimicry in rheumatoid arthritis. Curr Dir Autoimmun 2001; 3: 51–63.
  • 54
    Raza K, Falciani F, Curnow SJ, Ross E, Lee CY, Akbar A, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7: R784–95.
  • 55
    De Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005; 300: 124–35.
  • 56
    Svendsen PF, Andersen CB, Willcox NF, Coyle AJ, Holmdahl RF, Kamradt TF, et al. Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice. J Immunol 2004; 173: 7037–45.
  • 57
    Prakken BJ, Wauben M, Genini D, Samodal R, Barnett J, Mendivil A, et al. Artificial antigen presenting cells as a tool to exploit the immune synapse. Nat Med 2000; 6: 1406–20.
  • 58
    Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362: 1659–66.
  • 59
    Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531–62.
  • 60
    Shevach EM. Regulatory/suppressor T cells in health and disease [editorial]. Arthritis Rheum 2004; 50: 2721–4.
    Direct Link:
  • 61
    De Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, et al. CD4+CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172: 6435–43.
  • 62
    Van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50: 2775–85.
    Direct Link:
  • 63
    Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med 2004; 200: 273–6.
  • 64
    Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737–42.
  • 65
    Billetta R, Lanza P, Stoughton S, Ghahramani N, van Damme N, Giermakovska W, et al. Combination of peptide and IFN-β therapy suppresses experimental autoimmune encephalitis.
  • 66
    Schwartz RH. Natural regulatory T cells and self-tolerance. Nat Immunol 2005; 6: 327–30.
  • 67
    Schwartz M, Cohen IR. Autoimmunity can benefit self-maintenance. Immunol Today 2000; 21: 265–8.
  • 68
    Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202–8.
  • 69
    Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253–7.
  • 70
    Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 1581–8.
    Direct Link:
  • 71
    Vischer TL. Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis. Clin Rheumatol 1990; 9: 356–61.
  • 72
    Rosenthal M, Bahous I, Ambrosini G. Longterm treatment of rheumatoid arthritis with OM-8980: a retrospective study. J Rheumatol 1991; 18: 1790–3.
  • 73
    Polla BS, Baladi S, Fuller K, Rook G. Presence of hsp65 in bacterial extracts (OM-89): a possible mediator of orally-induced tolerance? Experientia 1995; 51: 775–9.
  • 74
    Vischer TL. A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 582–7.
  • 75
    Verstraeten A, Sileghem A, Dequeker J. OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis: a 12-month double-blind randomized study. Scand J Rheumatol 1990; 19: 422–31.
  • 76
    Trentham DE. Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Ann N Y Acad Sci 1996; 778: 306–14.
    Direct Link:
  • 77
    Trentham DE, Dynesius-Trentham RA, Orav JE, Combitchi D, Lorenzo C, Lea Sewell K, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727–30.
View Full Article (HTML) Get PDF (66K)